Grant of Share Options

Venture Life

25/07/2025 07:05

RNS Number : 5153S

Venture Life Group PLC

25 July 2025

 

25 July 2025

 

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Group")

 

Grant of Share Options

 

 

Venture Life (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that, pursuant to the Company's 2023 Long Term Incentive Plan ("LTIP"), it has granted options to subscribe for an aggregate of 2,500,000 ordinary shares of 0.3p each in the capital of the Company (the "Options") to the Company's Directors, as follows:

 

Director
Number of Options Granted
Exercise Price
Jerry Randall
1,000,000
57.70 pence
Daniel Wells
1,000,000
57.70 pence
Paul McGreevy
500,000
57.70 pence

 

The Options (which are subject to malus and clawback provisions) will vest after three years following publication of the Company's annual results for 2027 and will be exercisable within 7 years of vesting. Vesting is conditional on the achievement of certain performance criteria which include a total shareholder return and earnings per share measurement.

 

 

Further detail is provided below in accordance with Article 19.3 of the EU Market Abuse Regulation.

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Jerry Randall
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Venture Life Group plc
b)
LEI
213800S8CZUPLAB2KC70
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
57.70p
1,000,000
d)
Aggregated information
- Aggregated volume
- Price
n/a
e)
Date of the transaction
25 July 2025
f)
Place of the transaction
London Stock Exchange

 

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Daniel Wells
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Venture Life Group plc
b)
LEI
213800S8CZUPLAB2KC70
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
57.70p
1,000,000
d)
Aggregated information
- Aggregated volume
- Price
n/a
e)
Date of the transaction
25 July 2024
f)
Place of the transaction
London Stock Exchange


 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Paul McGreevy
2
Reason for the notification
a)
Position/status
Non-Executive Chair
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Venture Life Group plc
b)
LEI
213800S8CZUPLAB2KC70
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
57.70p
500,000
d)
Aggregated information
- Aggregated volume
- Price
n/a
e)
Date of the transaction
25 July 2024
f)
Place of the transaction
London Stock Exchange


 

For further information, please contact:

 

Venture Life Group PLC                                                                                                    +44 (0) 1344 578004

 

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker)                                             +44 (0) 20 7720 0500 

 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales) 

 

About Venture Life (www.venture-life.com)

 

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

 

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK,  Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHRIMLTMTBTBJA